SMARCA4-deficient Malignant Tumors clinical trials at UCSF
1 research study open to eligible people
SMARCA4-deficient malignant tumors are cancers caused by changes in the SMARCA4 gene. UCSF is studying how two immunotherapy drugs, nivolumab and ipilimumab, work together to treat these cancers in children and young adults. This research aims to find new treatment options.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include Alyssa Reddy.
Last updated: